Novel biallelic variants expand the SLC5A6-related phenotypic spectrum

Tess Holling, Sheela Nampoothiri, Bedirhan Tarhan, Pauline E. Schneeberger, Kollencheri Puthenveettil Vinayan, Dhanya Yesodharan, Arun Grace Roy, Periyasamy Radhakrishnan, Malik Alawi, Lindsay Rhodes, Katta Mohan Girisha, Peter B. Kang, and Kerstin Kutsche

The sodium (Na\(^+\)):multivitamin transporter (SMVT), encoded by SLC5A6, belongs to the sodium:solute symporter family and is required for the Na\(^+\)-dependent uptake of biotin (vitamin B\(7\)), pantothenic acid (vitamin B\(5\)), the vitamin-like substance α-lipoic acid, and iodide. Compound heterozygous SLC5A6 variants have been reported in individuals with variable multisystemic disorder, including failure to thrive, developmental delay, seizures, cerebral palsy, brain atrophy, gastrointestinal problems, immunodeficiency, and/or osteopenia. We expand the phenotypic spectrum associated with biallelic SLC5A6 variants affecting function by reporting five individuals from three families with motor neuropathies. We identified the homozygous variant c.1285 A > G [p.(Tyr162Cys)] in three affected siblings and a simplex patient and the maternally inherited c.485 A > G [p.(Tyr162Cys)] variant in the simplex patient of the third family. Both missense variants were predicted to affect function by in silico tools. 3D homology modeling of the human SMVT revealed 13 transmembrane helices (TMs) and Tyr162 and Ser429 to be located at the cytoplasmic facing region of TM4 and within TM11, respectively. The SLC5A6 missense variants p.(Tyr162Cys) and p.(Ser429Gly) did not affect plasma membrane localization of the ectopically expressed multivitamin transporter suggesting reduced but not abolished function, such as lower catalytic activity. Targeted therapeutic intervention yielded clinical improvement in four of the five patients. Early molecular diagnosis by exome sequencing is essential for timely replacement therapy in affected individuals.

INTRODUCTION

The sodium (Na\(^+\)):multivitamin transporter (SMVT) is a member of the sodium:solute symporter (SSS) family, a group of membrane proteins mediating the transport of the respective solute(s) by using the sodium gradient. SMVT is encoded by SLC5A6 and forms together with other members of the SSS family the solute carrier family 5 (SLC5) [1]. SMVT is required for the Na\(^+\)-dependent uptake of the water-soluble vitamins pantothenic acid (vitamin B\(5\)) and biotin (vitamin B\(7\)), the vitamin-like substance α-lipoic acid, and iodide [2–5]. The organic substrates of the SMVT are essential for human health [2]. Biotin is a coenzyme for several carboxylases, is involved in various metabolic reactions, and has a role in gene expression regulation, cell proliferation and survival [6]. Pantothenic acid is a component of coenzyme A and fatty acid synthase necessary for energy production and hormone synthesis [7]. α-Lipoic acid serves as a cofactor in redox reactions important for mitochondrial energy production and amino acid metabolism [8]. SMVT’s role in iodide transport and homeostasis is unknown up to date [2, 3].

Because SMVT substrates have versatile metabolic functions, deficiency of biotin, pantothenic acid and/or α-lipoic acid may lead to a broad range of clinical features in affected individuals. For example, biotin-dependent inherited disorders are holocarboxylase synthetase and biotinidase deficiency caused by biallelic variants in HLCS and BTD, respectively. Patients show a spectrum of clinical features including alopecia, skin rash, difficulties in breathing, hypotonia, seizures, developmental delay, feeding problems, vomiting, organic aciduria, and metabolic acidosis [6]. Thus, it is not surprising that compound heterozygous variants in SLC5A6 are associated with variable multisystemic manifestations in four patients reported to date. A 15-month-old patient with a c.280 C > T [p.(Arg94*)] variant in trans with the c.368 G > T [p.(Arg123Leu)] variant had failure to thrive, microcephaly, developmental delay, spastic cerebral palsy, brain atrophy, immunodeficiency, and osteopenia [9].
A 3-year-old girl with compound heterozygous SLC5A6 p.(Val141Alafs*34) and p.(Gln622Argfs*51) variants had failure to thrive and delayed motor development in infancy. At 17 months, she developed a severe metabolic crisis with hypoglycemia during gastroenteritis requiring resuscitation [10]. Two siblings with c.422_423del and c.1199 G > C/p.(Arg400Thr) biallelic variants had normal early development, followed by neurological regression and truncal ataxia with dyskinetic movements at the age of 12 and 14 months. One sibling developed seizures, cyclic vomiting and peripheral neuropathy at 7 years. The other sibling died at 2 years 7 months due to acute gastrointestinal hemorrhage [11]. Targeted vitamin replacement therapy resulted in clinical improvement [9–11]. Here we report five individuals from three families, including three siblings and two singletons, with biallelic variants in SLC5A6 and motor neuropathies.

SUBJECTS AND METHODS
Whole-exome sequencing and variant filtering
Whole-exome sequencing (WES) was performed in patient 1–2, patient 2–1 and parents, and patient 3–1.

For detailed descriptions of the applied sequencing techniques, see the online Supplementary Information.

SLC5A6 variants were described according to the GenBank reference sequences NM_021095.4 and NP_066918.4. The SLC5A6 variants were submitted to the LOVD database (https://databases.lovd.nl/shared/genes/SLC5A6), with LOVD Variant IDs 0000784069, 0000784070, 0000784071, 0000784072, and 0000813612.

Protein structure homology modeling
For detailed description, see the online Supplementary Information.

Expression constructs and mutagenesis
Human SLC5A6 coding region was PCR-amplified from fibroblast-derived cDNA. The PCR product was cloned into pENTR/D-TOPO vector (Thermo Fisher Scientific) according to the manufacturer’s protocol. The variants c.368 G > T [p.(Arg123Leu)], c.485 A > G [p.(Tyr162Cys)], and c.1285 A > G [p.(Ser429Gly)] were introduced in the In-Fusion HD Cloning Kit (Takara) according to the manufacturer’s protocol for mutagenesis. The SLC5A6 wildtype and the three mutant constructs were used for transferring the coding region into the mammalian expression vector pEGFP-N3 using the In-Fusion HD Cloning Kit (Takara) according to the manufacturer’s protocol for cloning. All constructs were sequenced for integrity.

Immunocytochemistry and confocal microscopy
A total of 150,000 HeLa cells were cultivated in Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; GE Healthcare) and penicillin-streptomycin (100 U/ml and 100 µg/ml, respectively; Thermo Fisher Scientific) on glass coverslips in 6-well plates. Cells were transiently transfected with C-terminally EGFP-tagged SLC5A6 expression constructs (wildtype and mutants) using jetOPTIMUS (Polyplus Transfection) with a DNA (µg):jetOPTIMUS (µL) ratio of 1:1 and cultivated for 48 h before fixing cells in 4% paraformaldehyde in phosphate-buffered saline (PBS). After extensive washing with PBS, cells were embedded in mounting solution (ProLong Diamond Antifade Mountant; Thermo Fisher Scientific). Cells were analyzed and images were acquired with the Leica TCS SP8 X confocal microscope.

RESULTS
Clinical summaries
Patient 1–1 is the third child born full term to healthy, non-consanguineous parents (Table 1 and Supplementary Table 1). She was a bit slower to walk and toilet train compared to her two older siblings. She had difficulty keeping up with peers in physical education. She was evaluated in the neurology clinic at 8 years 5 months for abnormal gait. She also had impaired balance, difficulty climbing stairs, frequent falls, difficulty squatting, and generalized fatigue. Initial physical exam was notable for prominent distal upper and lower extremity weakness as well as absent ankle reflexes. Muscle bulk was diffusely reduced, with significant atrophy of the thenar eminences and interosseous muscles bilaterally.

She was found to have mild dilated cardiomyopathy. Within a few months, she developed heart failure and required heart transplantation. NCS revealed borderline low amplitude tibial CMAPs for age and essentially normal sensory nerve action potentials (Supplementary Table 5). Needle EMG demonstrated mildly neurogenic motor unit morphology. A gastrocnemius muscle biopsy revealed a neurogenic pattern with fiber type grouping and no inflammation.

Patient 3–1 presented at 11 years with distal upper limb weakness (right > left). She experienced difficulty writing, buttoning, and opening bottle caps. She had generalized tremors. On physical examination, she had significant wasting of both hands (thenar > hypothenar), accompanied by weakness most prominently at the dorsal interossei, and to a lesser extent at the palmar interossei and thenar muscles, with relative sparing of the lumbrical muscles. There were tremors but no fasciculations in the upper extremities. There were mild cerebellar signs, including mild gaze-evoked nystagmus, dysdiadochokinesis, and difficulty tandem walking. NCS and needle EMG demonstrated mixed axonal and demyelinating motor findings corresponding to the areas of weakness on physical examination (Table 1 and Supplementary Table 1).

By 13 years, she had progressive worsening of the upper extremity symptoms, along with new proximal lower extremity weakness of 4 months’ duration, exhibited by inability to stand from a squatting position. She had developed nearly symmetrical weakness of hip extension, thigh adduction, knee flexion, and distal right upper extremity weakness, along with wasting of the thenar and hypothenar eminences and interossei bilaterally. She had difficulty opposing her thumb to the 4th and 5th fingers, but handgrip was good. Nerve conduction studies (NCS) revealed signs of focal demyelination in the right upper extremity (Supplementary Table 2). Needle electromyography (EMG) was not performed.

The 12-year-old sister of patient 1–1 (patient 1–2) had similar complaints that started at 10 years of age with difficulty holding a cup and fine motor impairments in the fingers, right more than left (Table 1 and Supplementary Table 1). She also denied difficulty in walking, climbing stairs and getting up from squatting position. She had premature graying of hair at the age of 4 months. Her past medical history was also notable for a right inguinal herniorrhaphy at 5 years of age. Physical examination revealed wasting of the thenar and hypothenar eminences, along with the interossei bilaterally. She had mild contractures of both thumbs and the left index finger. She could not oppose her thumb with the 4th and 5th fingers. She displayed mild weakness of handgrip. NCS demonstrated low amplitude left median CMAPs and absent right median CMAPs. Needle EMG demonstrated chronic denervation, suggesting the presence of a motor neuropathy or neuronopathy (Supplementary Table 3). A left peroneus muscle biopsy demonstrated neurogenic features.

The younger brother of patients 1–1 and 1–2 (patient 1–3) was asymptomatic. Clinical evaluation at 6 years 6 months showed mild bilateral handgrip weakness (Table 1 and Supplementary Table 1). NCS showed demyelinating and axonal features in the upper extremities (Supplementary Table 4).

Patient 2–1 is the third child born full term to healthy, non-consanguineous parents (Table 1 and Supplementary Table 1). She had premature graying of hair at the age of 4 months. Her left hand function was normal. She denied difficulty in walking, climbing stairs or rising from a squatting position. The initial physical examination was remarkable for mild bilateral handgrip weakness (Table 1 and Supplementary Table 1). She also denied difficulty in walking, climbing stairs or rising from a squatting position. The initial physical examination was remarkable for mild bilateral handgrip weakness (Table 1 and Supplementary Table 1). She also denied difficulty in walking, climbing stairs or rising from a squatting position. The initial physical examination was remarkable for mild bilateral handgrip weakness (Table 1 and Supplementary Table 1).
Table 1. Main clinical features in five patients with biallelic SLC5A6 variants.

|                  | Patient 1–1 | Patient 1–2 | Patient 1–3 | Patient 2–1 | Patient 3–1 |
|------------------|-------------|-------------|-------------|-------------|-------------|
| Variant          | NM_021095.4 NP_066918.4 | c.1285 A > G p.(Ser429Gly) Homozygous | c.1285 A > G p. (Ser429Gly) Homozygous | c.280 C > T p.(Arg94*) c.485 A > G p.(Tyr162Cys) | c.1285 A > G p.(Ser429Gly) Homozygous |
| Demographics     |             |             |             |             |             |
| Age of onset     | 13 y 6 m    | 10 y        | 6 y 9 m     | 8 y 5 m     | 8 y         |
| Age of diagnosis | 14 y        | 11 y 9 m    | 6 y 9 m     | 9 y 3 m     | 13 y        |
| Sex              | Female      | Female      | Male        | Female      | Female      |
| Measurements     |             |             |             |             |             |
| Age              | 14 y        | 11 y 9 m    | 6 y 9 m     | 9 y 3 m     | 13 y        |
| Weight (centile) | 34 kg (<1st) (−2.44) | 26.3 kg (1st) (−2.55) | 19.5 kg (14th) (−1.06) | 23.5 kg (7th) (−1.44) | 48 kg (59th) (−0.23) |
| Height (centile) | 151 cm (8th) (−1.43) | 133.5 cm (2st) (−2.12) | 119 cm (41st) (−0.22) | 131.7 cm (35th) (−0.39) | 148 cm (82th) (−1.31) |
| OFC (centile)    | 54 cm (37th) (−0.33) | 53.5 cm (54th) (+0.10) | 52 cm (49th) (−0.02) | ND          | ND          |
| Variant Neuromuscular Exam Findings at Diagnosis |             |             |             |             |             |
| Neurological development | Normal | Normal | Normal | Normal | Normal |
| Muscle Bulk      | Atrophy of thenar and hypothenar eminence (more prominent on the right hand); bilateral atrophy of interosseous muscles | Atrophy of thenar and hypothenar eminence (more prominent on the right hand); bilateral atrophy of interosseous muscles | Normal | Muscle bulk reduced throughout; bilateral atrophy of thenar eminence and interosseous muscle | Atrophy of thenar and hypothenar eminence (more prominent on the right hand and thenar eminence) and interosseous muscles |
| Muscle strength  |             |             |             |             |             |
| Neck flexion/extension | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
| Upper extremity  | Difficulty in pincer grasp and fine movements of fingers and opposition of thumb with 4th and 5th fingers; contracture of bilateral 4th and 5th toes | Distal weakness of hands; difficulty in pincer grasp and opposition of thumb with 4th and 5th fingers; contracture of bilateral thumbs and right index finger | Mild hand grip weakness | Deltoids 3 Triceps 5 Biceps 4 Wrist Flexion & extension 4/5 Extensor digitorum communis 4 First dorsal interosseous 2 Abductor digitimimini 2 Abductor pollicis brevis 0 Grip 4 | Shoulder, elbow, and wrist flexion/extension 5/5 Distal weakness of distal upper extremity including palmar and dorsal interossei, abductor pollicis, adductor pollicis, opponens pollicis, and flexor pollicis brevis. Lumbrical 5 Grip 4 |
| Lower extremity  | No proximal muscle weakness of lower limbs | Bilateral weak ankle dorsiflexion and bilateral 4th and 5th toes; no proximal muscle weakness of lower limbs | Normal power in muscles of lower limb | Gluteus medius 5 Gluteus maximus 5 Iliopsoas 4 Quadriceps 5 Hamstrings 3 Tibialis anterior 3 Tibialis posterior 2 Peroneus longus/brevis 5 Extensor hallucis longus 3 Gastrocnemius 4 | b/l hip flexion 4 (left > right) Extension 5 Adduction 5 Abduction 5 Knee flexion 4− (left > right) Knee extension 5 Ankle dorsiflexion 4 Plantar flexion 5 (Eversion weaker than Inversion on the right Inversion weaker than eversion on the left) |
|                      | Patient 1–1                          | Patient 1–2                          | Patient 1–3                          | Patient 2–1                          | Patient 3–1                          |
|----------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Reflexes             | Sluggish in upper and lower limbs    | Sluggish in upper and lower limbs    | Deep tendon reflexes in upper and lower limbs are normal | 2+ in upper extremity; absent in lower extremity; down going plantar response B/L | Brisk in upper extremity, sluggish in lower extremity and absent ankle reflexes B/L |
| Sensation            | Normal                               | Normal                               | Normal                               | Normal                               | Normal                               |
| Gait                 | Normal                               | Normal                               | Normal                               | Unsteady with smaller steps; unable to perform toe/heel walking and tandem walking | Ataxic gait with minimal waddling; unable to perform tandem walking. Dysmetria, dysdiadokokinesia +(more on left side) |
| Diagnostic Workup    | Needle EMG                           | Chronic denervation                  | ND                                   | The left anterior tibialis and medial gastrocnemius muscles displayed polyphasic motor units with mildly prolonged durations and the left first dorsal interosseous displayed mildly prolonged motor unit durations | Initial study at 11 y showed denervation-reinnervation pattern at the right FDI, with normal patterns at the right TA, deltoid, and brachioradialis. Follow-up study at 13 y showed discrete recruitment patterns at all muscles tested |
| Muscle/nerve biopsy  | ND                                   | Muscle biopsy: neurogenic pattern    | ND                                   | Muscle biopsy: neurogenic pattern with scattered small atrophic angulated myofibers of both types and fiber type grouping. Sural nerve biopsy: normal | ND                                   |
Genetic and biochemical findings

Singleton WES was performed on patient 1–2. We filtered variants assuming a recessive inheritance pattern and detected the homozygous variant c.1285 A > G in SLC5A6 predicting the amino acid substitution p.(Ser429Gly) (Tables 1 and 2). The variant is absent from public databases including gnomAD and is predicted to affect function by the in silico tools CADD, REVEL, and M-CAP. Serine 429 is intolerant of variation as predicted by MetaDome (Table 2) [12]. Sanger sequencing confirmed the homozygous SLC5A6 variant in patients 1–1, 1–2, and 1–3, and also confirmed that each asymptomatic parent harbored the heterozygous variant (Supplementary Fig. 1a).

On trio-WES, patient 2–1 was found to have a maternally inherited c.280 C > T, p.(Arg94*) variant and a paternally inherited c.485 A > G, p.(Tyr162Cys) variant in SLC5A6 (Tables 1, 2). The c.280 C > T, p.(Arg94*) variant has a worldwide minor allele frequency (MAF) of 0.00002 (gnomAD) and has been described to affect function [9]. The unreported variant c.485 A > G has a worldwide MAF of 0.00002 (gnomAD) and is predicted to affect function. Tyrosine 162 is predicted to be intolerant of variation (Table 2). The variants in the trio were confirmed via Sanger sequencing (Supplementary Fig. 1b).

Singleton WES in patient 3–1 revealed the same homozygous SLC5A6 variant as identified in family 1: c.1285 A > G, p.(Ser429Gly) (Tables 1, 2). Sanger sequencing confirmed the homozygous variant in patient 3–1 and the heterozygous variant in the unaffected parents (Supplementary Fig. 1c).

Analysis of exome sequencing data in patients 1–2 and 3–1 for regions of homozygosity (ROHs) revealed 15 ROHs with a total of 54 Mb in patient 1–2 (Supplementary Table 7) and 14 ROHs with a total of 67.07 Mb in patient 3–1 (Supplementary Table 8) suggesting parental consanguinity in both families. We identified a homozygous region on chromosome 2 of 7.34 Mb (chr2:25,376,564-32,713,706) and of 5.9 Mb (chr2:22,865,260-28,762,031) in patient 1–2 and 3–1, respectively, that includes the SLC5A6 variant c.1285 A > G (Supplementary Tables 7, 8). The region contains a 3.39-Mb (chr2:25,376,564-28,762,031) shared haplotype in both patients suggesting remote relatedness (Supplementary Table 9).

GeneMatcher [13] and medical care of the patients 1–1, 1–2, 1–3, and 3–1 by one of the authors (S.N.) permitted co-ordinated investigation of the families. Metrics from gnomAD show fewer than expected missense variants (o/e = 0.76), indicating that SLC5A6 is slightly intolerant of missense variants [14]. We believe the biallelic SLC5A6 variants to underlie the motor neuropathies in the five patients described here as the detected variants were absent or rare in population databases and predicted to affect function, and biallelic SLC5A6 variants have been reported to cause disease [9–11].

Biotin deficiency was confirmed in serum of patient 1–2 (Table 3). As this biochemical test was not available for the patients from India, we determined that pyruvate carboxylase activity was similar between patient 1–2 and control fibroblasts (Supplementary Fig. 2). Plasma biotinidase activity in all patients was normal (Table 3). We did not find any rare variants affecting function in BTD in the exome data of patients 1–2, 2–1, and 3–1. The exclusion of biotinidase deficiency in all patients support the
Table 3. Interval clinical improvement in five patients with biallelic SLC5A6 variants.

| Patient 1-1 | Patient 1-2 | Patient 1-3 | Patient 2-1 | Patient 3-1 |
|-------------|-------------|-------------|-------------|-------------|
| Age at initiation of therapy | 15 y 1 m | 12 y 10 m | 7 y 10 m | 9 y 3 m | 13 y 6 m |
| Serum vitamin levels before treatment | Not available | Not available | Not available | Vitamin B7 (biotin) <100.0 pg/mL | Not available |
| Initial therapy | Biotin 5 mg BID | Biotin 5 mg BID | Biotin 5 mg BID | Biotin 5 mg BID | Biotin 100 mg daily |
| Therapy adjustments | Pantothenic acid 500 mg daily | Pantothenic acid 500 mg daily | Pantothenic acid 500 mg daily | Pantothenic acid 500 mg daily | Lipoic acid 150 mg BID |
| Interval history | Hand grip and finger strength improved | Hand grip and finger strength improved | No significant clinical changes | Her stamina and strength improved; she is able to walk without tripping | No significant clinical changes |
| Age/length/weight (z score) | 15 y 8 m 149 cm (−3.16) 36 kg (−2.07) | 13 y 6 m 141 cm (−3.63) 28 kg (−2.68) | 8 y 6 m 125 cm (−0.98) 20 kg (−2.32) | 10 y 141.2 cm (0.45) 27.3 kg (−1.03) | 13 y 9 m 50 kg (0.04) |
| Vitamin levels | Biotinidase 4.61 [4.5–12.0 nmol/mL/ min] | Biotinidase 5.19 [4.5–12.0 nmol/mL/ min] | Biotinidase 4.91 [4.5–12.0 nmol/mL/ min] | Biotinidase 6.7 [5.1–11.9 nmol/mL/ min] | Biotinidase 5.58 [4.5–12.0 nmol/mL/ min] |

Neuromuscular exam findings

| Muscle bulk | Muscle bulk reduced throughout; atrophy of thenar and hypothenar eminence (more prominent on the right hand); bilateral atrophy of interosseous muscles | Atrophy of thenar and hypothenar eminence (more prominent on the right hand); bilateral atrophy of interosseous muscles | Bilateral atrophy of interosseous muscles (more prominent on the right hand) | Muscle bulk reduced throughout; bilateral atrophy of thenar eminence and interosseous muscle | Atrophy of thenar and hypothenar eminence (more prominent on the right hand); thenar > hypothenar atrophy; interosseous muscles atrophy noted |
| Neck | Flexion & extension 5/5 | Flexion & extension 5/5 | Flexion & extension 5/5 | Flexion & extension 5/5 | Flexion & extension 5/5 |
| Upper extremity | Deltoids 5 | Triceps 5 | Biceps 5 | Wrist flexion & extension 5/5 | Extensor pollicis brevis 4 |
| Lower extremity | Gluteus medius 4 | Gastrocnemius 4 | Tibialis anterior 5 | Gluteus medius 5 | Quadriceps 5 |

Her stamina and strength improved. She is able to walk without tripping.
association of biallelic SLC5A6 variants with motor neuropathies in the current cohort.

Human SMVT 3D homology modeling

Knowledge of the human SMVT structure-function relationship is limited as structural approaches using purified SMVT are missing [2]. SMVT together with the sodium:galactose symporter SGLT1, encoded by SLC5A1, and the sodium:iodide symporter NIS, encoded by SLC5A5, belong to the SSS family that contain 10–14 transmembrane α-helices (TM) [1]. To gain insight into the effects of SLC5A6 amino acid substitutions reported previously and here (Table 2), we aligned the amino acid sequence of human SMVT with the sodium:galactose symporter from *Vibrio parahaemolyticus* (vSGLT) (Supplementary Fig. 3). This alignment confirmed 13 TMs for SMVT with an extracellular N-terminus, a large extracellular loop between TM12 and TM13, and a cytoplasmic C-terminus (Fig. 1a and Supplementary Fig. 3) [2].

We next generated a 3D model of SMVT using vSGLT as template (Fig. 1b) [15, 16]. The structure of the N- and C-terminus, TM1, the TM1-TM2 loop, and the large TM12-TM13 loop could not be predicted due to missing residues in the vSGLT crystal structure and limitations of homology predictions for random coiled regions (shown as dashed lines in Fig. 1a, b). The previously reported disease-associated substitutions p.(Arg123Leu) and p.(Arg400Thr) (Table 2) and p.(Tyr162Cys) and p.(Ser429Gly) identified here do not cluster in a specific SMVT region (Fig. 1a, b). Arg123 is located at the intracellular cap of TM3 and Arg400 in the cytoplasmic facing region of TM10 (Fig. 1a, b). TM10 in vSGLT has a supporting function by stabilizing the central helices [15]. Tyr162 is located at the cytoplasmic facing region of TM4 (Fig. 1a, b). In vSGLT, TM4 is one of the seven central helices. The correct positioning of the central helices extends the cavity from just below the substrate-binding site to the intracellular space and contributes to side chain interactions for ligand sensitivity [15]. Except this, the extracellular facing ends of TM2 and TM4 form extensive contacts with helix 8b, which is localized in the extracellular linker of TM8 and TM9 and straddles the membrane plane [15]. In the SMVT model, Tyr162 is in spatial proximity to helix 8b at the extracellular facing region of TM4 (Fig. 1b). Substitution of a large hydrophobic amino acid like tyrosine to a smaller amino acid like cysteine could cause a loss of side chain interactions [17]. Correct positioning of TM4 in the membrane or the interaction between TM4 and helix 8b could be affected. Ser429 is located in TM11 (Fig. 1a–c) which is probably involved in substrate binding. Importantly, structural rearrangement of TM11 is possibly important for substrate transport [15]. Substitution of a polar serine residue by a small and flexible glycine could affect the arrangement of the transmembrane helices and/or substrate binding.

Functional studies of the SLC5A6 variants p.(Tyr162Cys) and p.(Ser429Gly)

To experimentally analyze the effect of the SLC5A6 variants p.(Tyr162Cys) and p.(Ser429Gly) on SMVT function, we transiently transfected HeLa cells with SLC5A6-EGFP wildtype construct and the mutant constructs SLC5A6-Y162C-EGFP, SLC5A6-S429G-EGFP, and SLC5A6-R123L-EGFP and determined the subcellular distribution of the SMVT by immunofluorescence analysis. We used the SLC5A6-R123L-EGFP construct as control as the previously reported p.(Arg123Leu) variant causes intracellular retention of the SMVT [9]. HeLa cells expressing EGFP alone showed an even green fluorescence in the cytoplasm (Fig. 2), while wild-type SLC5A6-EGFP displayed plasma membrane localization (Fig. 2). The two EGFP-tagged SLC5A6 mutants Y162C and S429G were localized at the plasma membrane (Fig. 2), while the SLC5A6-R123L-EGFP mutant was mainly present in the cytoplasm (Fig. 2). These data show that p.(Tyr162Cys) and p.(Ser429Gly) do not affect SMVT plasma membrane localization that is contrast to p.(Arg123Leu) that leads to intracellular retention of the transporter.
Treatment outcomes
Upon identification of biallelic SCL5A6 variants, patients 1–1, 1–2, and 1–3 were treated with biotin (5 mg twice daily). After 6 months of treatment, only patient 1–2 had slight improvement in hand strength. Therapy was later extended to biotin 10 mg, pantothetic acid 250 mg, and lipoic acid 150 mg, all dosed twice daily. The most recent regimen was biotin 100 mg, pantothentic acid 500 mg, and lipoic acid 300 mg, all dosed daily. After one month of treatment, hand grip and finger strength were improved in patients 1–1 and 1–2, while patient 1–3 was unchanged (Table 3). Due to restrictions related to SARS-CoV-2, these medications were unavailable to the three siblings for six months prior to this last dose adjustment.

In patient 2–1, biotin (5 mg twice daily), pantothenate (250 mg daily), and α-lipoic acid (150 mg daily) were initiated at 9 years 3 months (Table 3). These doses were doubled 3 months later. At 9 months, the child exhibited marked improvement in weight, height, balance, muscle strength, and exercise tolerance. Her gait was near normal at the last follow-up and she was able to keep up with her peers. However, she had residual mild distal upper extremity weakness.

At the age of 13 years, patient 3–1 was empirically treated with intravenous methylprednisolone for 5 days followed by an oral steroid taper. She began supplementation with riboflavin, coenzyme Q10, pyridoxine, vitamin E, and carnitine (Table 3). There was minimal improvement in gait and coordination over the
next month. Upon identification of the SLC5A6 variant, she was initiated on biotin and α-lipoic acid (Table 3). Five months later, she reported improvement in gait and coordination.

**DISCUSSION**

Dysfunction of the Na⁺:vitamin transporter causes phenotypic heterogeneity, including failure to thrive, developmental delay or early normal development followed by developmental regression, seizures, diarrhea or vomiting, immunodeficiency, and/or osteopenia [9–11]. We further expand the phenotypic spectrum associated with biallelic SLC5A6 variants by reporting five individuals from three families with pleomorphic motor neuropathies that had both axonal and demyelinating features. Findings on NCS were sometimes asymmetric, suggesting that the nerve damage may be non-uniform in some instances. While the presentations in the patients reported here define the mild end of the spectrum, the phenotypes previously reported patients are more severe [9–11]. Biotin deficiency was detected in serum of patient 2–1, while serum vitamin levels could not be determined in the four affected individuals from India (Table 3). Measurement of circulating biotin in serum and plasma is not a reliable measure of status because depressed serum biotin is not consistently observed in biotin deficiency [18]. By measuring the activity of the biotin-dependent pyruvate carboxylase in fibroblasts of patient 1–2 we did not obtain evidence for biotin deficiency in this patient. This was not surprising as normal skin-derived cells show low sensitivity to biotin depletion [19]. In a boy with biotin dependency and suspected inherited defect in biotin transport, normal carboxylase activities in fibroblast extracts were identified. An acute illness elicited a severe metabolic disorder with an encephalopathic episode at 18 months that improved rapidly with biotin supplementation [20]. In retrospect, this patient likely had biallelic SLC5A6 variants although SLC5A6 cDNA sequencing did not reveal variants affecting function [20]. A previously reported patient with biallelic SLC5A6 variants had a severe metabolic crisis with encephalopathy [10]. These data suggest that patients carrying biallelic SLC5A6 variants with a severe impact on SMVT function can present with a state of precarious biotin homeostasis that can lead to life-threatening metabolic crises.

Mice with intestine-specific Slc5a6 knockout exhibit growth failure, decreased bone density and length, lethargy, hunched back posture, and gut inflammation [21, 22]. Biotin and pantothenic acid supplementation rescued the phenotype [23]. Two previously reported patients with biallelic SLC5A6 variants also showed failure to thrive [9, 10] and triple vitamin replacement therapy, likely via a simple diffusion mechanism, had beneficial effects in the three live patients [9–11]. In our cohort, patient 2–1 showed unequivocal improvement with vitamin therapy; the patients in families 1 and 3 did not show consistent improvements, indicating that responses to vitamin therapy are not uniform.

Four of the nine patients with biallelic SLC5A6 variants reported to date (including the current cohort) carry early nonsense or frameshift variants together with a missense variant [9, 11]. One patient has an early frameshift in combination with a late frameshift variant [10], and four patients reported here are homozygous for the same missense variant. Is there any possible correlation between genotypes and phenotypes? One individual carries the null allele p.(Val141Alafs*34) as it leads to nonsense-mediated mRNA decay (NMD) [11], similar to the nonsense variant p.(Arg94*) reported in another individual [9]. In contrast, the late frameshift variant p.(Gln622Argfs*51) is located in the last SLC5A6 exon, likely escapes NMD and leads to production of a C-terminally truncated SMVT. The relatively mild phenotype in the patient with p.(Val141Alafs*34) and p.(Gln622Argfs*51) variants suggests residual functioning of the C-terminally altered vitamin transporter [10]. Consistent with this, the C-terminus of SMVT is important for plasma membrane targeting [24, 25]. p.(Arg123Leu) and p.(Arg400Thr) impair biotin uptake by the ectopically expressed SMVT mutants [9, 11] and SMVT-Arg123Leu is retained in the endoplasmic reticulum [9]. The data suggest that the four reported patients with a multisystemic disease and/or near-fatal events carry a null allele in trans with a second allele that produces a functionally impaired SMVT transporter [11].

It is plausible that the p.Tyr162Cys and p.Ser429Gly variants identified in individuals affected by motor neuropathies have a milder effect on Na⁺:vitamin transporter function. Our studies showed that p.Tyr162Cys and p.Ser429Gly did not impact plasma membrane targeting of the SMVT, suggesting that both SMVT mutants have reduced function, i.e., a lower catalytic rate. This assumption is corroborated by the finding that Ser429 in SMVT corresponds to Gln429 in vSGLT (Fig. 1c), a residue adjacent to Gln428 (Fig. 1c), which is a key residue involved in substrate binding [15, 26]. An amino acid substitution changing the corresponding glutamine, Gln457, to arginine in human SGLT1 (Fig. 1c) and affecting function has been reported. SGLT1-Gln457Arg is present at the plasma membrane and binds the substrate but does not transport the substrate through the membrane [27, 28]. The effect of the p.Tyr162Cys change on SMVT function is difficult to predict. There are no disease-associated amino acid changes in SGLT1 or NIS known to date that affect the corresponding residue. As Tyr162 is in spatial proximity to helix 8b at the extracellular facing of TM4 (Fig. 1b), we searched for amino acid substitutions affecting function located in the extracellular helix 8b of other sodium:solute symporters. In SGLT1 substitutions changing Tyr366 and Leu369 and affecting function are located in the extracellular helix 8b, which is in spatial proximity to the extracellular facing end of TM4 [29, 30]. Functional studies revealed a reduced uptake of the substrate by the SGLT1-Leu369Ser mutant [29]. A similar effect could be possible for the SMVT-Y162C mutant. Variants affecting function in SLC25A46, encoding a mitochondrial carrier, can destabilize the carrier, while other missense variants affect the formation/stability of higher molecular weight complexes [32]. Together, missense variants in transporters can cause loss of function, while other amino acid changes leave the protein intact and impair its function.

Is there any link between reduced levels of biotin, pantothenic acid and/or α-lipoic acid and neuropathy? One previously reported patient with biallelic SLC5A6 variants developed mixed axonal and demyelinating sensorimotor peripheral neuropathy from 3 years of age on that resolved post vitamin treatment. The patient’s sibling died in early childhood. Histopathological analysis demonstrated peripheral nerves with axonal irregularity and patchy denervation atrophy in skeletal muscle biopsy [11]. These findings suggest that reduced biotin, pantothenic acid and/or α-lipoic acid levels may be neurotoxic and contribute to the peripheral neuropathies seen in some individuals with biallelic SLC5A6 variants. Various combinations of peripheral neuropathy, myelopathy, spastic paraparesis, and optic neuropathy have been described in individuals with biallelic BTD variants. Partial reversal of symptoms in these patients with biotin therapy underscores a role of biotin deficiency in peripheral neuropathy [33]. Impaired intestinal biotin uptake has been hypothesized to contribute to peripheral neuropathy in individuals with alcoholism [6, 34]. Successful biotin and/or α-lipoic acid supplementation in individuals with peripheral neuropathy associated with diabetes and alcoholism further supports the association of peripheral neuropathy with reduced levels of these nutrients [35–37].

In conclusion, we report biallelic SLC5A6 variants affecting function in individuals with motor neuropathies. Plasma membrane localization of the SMVT-Y162C and SMVT-S429G mutants

European Journal of Human Genetics (2022) 30:439 – 449
underscores reduced but not abolished function of the multivitamin transporter. Prompt molecular genetic diagnosis is of importance for these patients as vitamin supplementation has a therapeutic benefit.

DATA AVAILABILITY
All data generated or analysed during this study are included in this published article and its Supplementary Information files.

REFERENCES
1. Gyimesi G, Pujol-Gimenez J, Kanai Y, Hediger MA. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflug Arch. 2020;472:1177–206.
2. Quick M, Shi L. The sodium/multivitamin transporter: a multipotent system with therapeutic implications. Vitam Horm. 2015;98:63–100.
3. de Carvalho FD, Quick M. Surprising substrate versatility in SLC5A6: Na+–coupled I- transport by the human Na+-/multivitamin transporter (hSMVT). J Biol Chem. 2011;286:131–7.
4. Wang H, Huang W, Fei YJ, Xia H, Yang-Feng TL, Leibach FH, et al. Human placental Na+-dependent multivitamin transporter. Cloning, functional expression, gene structure, and chromosomal localization. J Biol Chem. 1999;274:14875–83.
5. Prasad PD, Wang H, Kekuda R, Fujita T, Fei YJ, Devoe LD, et al. Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitaminate transporter mediating the uptake of pantothenate, biotin, and lipoate. J Biol Chem. 1998;273:7501–6.
6. Said HM. Biotin: biochemical, physiological and clinical aspects. Subcell Biochem. 2012;56:1–19.
7. Lykstad J, Sharma S. Biochemistry, Water Soluble Vitamins. StatPearls. Treasure Island (Fl). 2021.
8. Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inherit Metab Dis. 2014;37:553–63.
9. Subramanian VS, Constantinescu AR, Benke PJ, Said HM. Mutations in SLC5A6 associated with brain, immune, bone, and intestinal dysfunction in a young child. Hum Genet. 2017;136:253.
10. Schwantje M, de Sain-van der Velden M, Jans J, van Gassen K, Dorrepaal C, Koop KS, et al. Genetic defect of the sodium-dependent multivitamin transporter: a treatable disease, mimicking biotinidase deficiency. JIMD Rep. 2019;48:11–4.
11. Byrne AB, Arts P, Polyak SW, Feng J, Schreiber AW, Kassahn KS, et al. Identification and targeted management of a neurodegenerative disorder caused by bi-allelic mutations in SLC5A6. NPJ Genom Med. 2019;4:28.
12. Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome: pan-ethnicity analysis of genetic variants through aggregation of homologous human protein domains. Hum Mutat. 2019;40:1030–8.
13. Sobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A. New tools for Mendelian disease gene identification: PhenomDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene. Hum Mutat. 2015;36:425–31.
14. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.
15. Faham S, Watanabe A, Besserer GM, Cascio D, Specht A, Hirayama BA, et al. The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/galactose cotransport, the human Na+/glucose cotransporter (SGLT1) trafficking and function. Nature. 2010;468:988–91.
16. Kellom E, Stepien K, Rice G, Wolf B. Biotinidase deficiency is a rare, potentially treatable cause of peripheral neuropathy with or without optic neuropathy in adults. Mol Genet Metab Rep. 2021;26:100696.
17. Ziegler D, Papanas N, Schnell O, Nguyen BDT, Nguyen KT, Kulkantrakorn K, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12:646–75.
18. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Alter Med Rev. 2006;11:294–329.
19. Koutsiokos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother. 1990;44:511–4.

ACKNOWLEDGEMENTS
We thank all patients and family members for their participation in this study, Dennis Zomdø for skillful technical assistance, and the UKE Microscopy Imaging Facility (UMIF) for technical support.

AUTHOR CONTRIBUTIONS
TH performed homology modelling and the experimental work, analysed and interpreted data, and wrote the manuscript. SN and BT examined the patients, characterised the clinical features, and wrote the manuscript. PES, MA, PR, LR and KMG performed WES and/or analysed the WES data and/or wrote the manuscript. KPV, DY, and AGR examined the patients. PKB designed and supervised the study, examined the patients, characterised the clinical features, and wrote the manuscript. KK designed and supervised the study, interpreted data, and wrote the manuscript. All authors edited or commented the manuscript.

FUNDING
This work was supported by a grant from the Deutsche Forschungsgemeinschaft (KO 4576/1-2 to KK). Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS
LR is an employee of GeneDx, Inc and PR is an employee and KMG is a director of Suma Genomics Pvt. Ltd. All other authors declare no competing interests.

ETHICAL APPROVAL
The parents of three siblings (patients 1, 2, and 3) provided informed consent for their participation in the study, clinical data and specimen collection, genetic analysis, and publication of relevant findings. Informed consent was obtained for patient 2–1 and her parents (family 2) under a protocol approved by the Institutional Review Board of the University of Florida.
